Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Purdue Files Show It Knew Cuts Wouldn’t Kill OxyContin Sales (2)

Dec. 10, 2019, 5:35 AM

When Purdue Pharma LP cut the last of its sales force in June 2018, some analysts figured the move by the maker of OxyContin painkillers would help address a U.S. opioid-addiction epidemic the company had been accused of creating.

But documents filed Monday by a group of state attorneys general in the company’s bankruptcy suggests the maneuver wasn’t quite the sacrifice it seemed.

Purdue had already calculated that “carry over” sales from its past aggressive marketing of the drugs would continue to generate hundreds of millions of dollars through 2022, even without sales staff encouraging doctors to prescribe it, according ...